Research To Practice | Oncology Videos Research To Practice

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:
Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications

Featuring an interview with Dr Joshua Richter, including the following topics:
Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00) Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18) Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53) Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40) Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34) Racial and ethnic disparities in the treatment of MM (32:09) CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics:
Introduction (0:00) Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40) Role of Immunotherapy in Intermediate-Stage HCC (17:02) First-Line Therapy for Advanced HCC (19:56) Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29) Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02) Potential Role of HER2-Targeted Therapy for BTCs (1:17:16) CME information and select publications
 

Featuring perspectives from Dr Adam M Brufsky, including the following topics:
Review of Local Therapy (0:00) Treatment Advances for HER2 Positive Early-Stage Breast Cancer (18:34) Case: A woman in her early 60s with ER-positive, HER2-positive (IHC 3+) with infiltrating ductal carcinoma who received T-DM1 with an aromatase inhibitor (19:37) Case: A woman in her early 50s with ER-positive, HER2-positive (IHC 3+) who received TCHP followed by a mastectomy (56:36) Beyond the Guidelines Survey and HERRISK (1:02:33) Trials in Progress (1:14:24) CME information and select publications

Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O’Malley and Dr Shannon N Westin, including the following topics:
Introduction (0:00) Incidence and Biology of Endometrial Cancer (EC) (9:30) Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24) First-Line Therapy for Primary Advanced or Recurrent EC (28:28) Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08) Potential Role of Selinexor in the Management of EC (1:13:20) Incidence and Management of HER2-Positive EC (1:22:51) NCPD information and select publications

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics:
Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00) Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11) Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33) NCPD information and select publications